NCT06980272View on ClinicalTrials.gov

SSGJ-707 in Advanced Non-Small Cell Lung Cancer

PHASE3RecruitingINTERVENTIONAL

Enrollment

420

Participants

Timeline

Start Date

June 20, 2025

Primary Completion Date

July 30, 2026

Study Completion Date

December 31, 2028

Conditions

Advanced Non-Small Cell Lung Cancer

Interventions

DRUG

SSGJ-707

Subjects receive SSGJ-707 intravenously.

DRUG

Pembrolizumab

Subjects receive Pembrolizumab intravenously.

Trial Locations (1)

Unknown

RECRUITING

The Shanghai East Hospital, Shanghai

All Listed Sponsors

lead

Shenyang Sunshine Pharmaceutical Co., LTD.

INDUSTRY